Tofacitinib: cardiovascular and cancer risks
Janus kinase inhibitors are oral targeted agents used for the treatment of various chronic inflammatory diseases including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and atopic dermatitis.